Massive Bio is introducing our latest innovation, the Drug Utilization Optimizer (#DUO), at the ASCO Annual Meeting 2024 in Chicago! Building on the success of our SYNERGY-AI platform, DUO is set to transform how pharmaceutical commercial teams target and engage physicians. This innovative analytics and real-time notification platform provides unparalleled insights and efficiencies, allowing commercial teams to analyze the competitive landscape with up-to-date and accurate data. DUO connects with the right physicians, identifies relevant patients quickly and efficiently, increases brand revenues, and reduces the cost of sales. Unlike traditional real-world data companies, we improve operational efficiency and facilitate patient access to medicines by providing real-time and detailed insights. We recognize the challenges in cancer clinical trials and continue to work rapidly to bring more hope. Visit our booth at #ASCO24 to learn more about DUO and see a demo and click on the link below. 👉🏻 https://bit.ly/3yL8eGo Booth: #29137 Selin Kurnaz, PhD, Arturo LoAIza-Bonilla MD, Çağatay M. Çulcuoğlu, Toygun Onaran, Oz Huner, Aslan Aslanağı, Eren Caskurlu, Hakki Isik, PMP, Mert Sarı, Ertuğrul T., Toykan Dogan, MCogSc, #MassiveBio #ClinicalTrials #Innovation #Oncology #AIinHealthcare
Massive Bio’s Post
More Relevant Posts
-
Biotech and pharma companies - How do we determine the most efficient regulatory path for codeveloped companion diagnostic tests (CDx)? A CDx can significantly maximize return on investment in clinical trials, but transitioning from a research-grade to a clinical-grade assay can present resource management challenges, especially for emerging companies. Regulatory experts Mwango Kashoki and Sinan Sarac share how to minimize time and resources in our New Medicines, Novel Insights Oncology report: https://lnkd.in/e-iG-67V #PrecisionOncology #Regulatory #NovelInsights
-
-
Biotech and pharma companies - How do we determine the most efficient regulatory path for codeveloped companion diagnostic tests (CDx)? A CDx can significantly maximize return on investment in clinical trials, but transitioning from a research-grade to a clinical-grade assay can present resource management challenges, especially for emerging companies. Regulatory experts Mwango Kashoki and Sinan Sarac share how to minimize time and resources in our New Medicines, Novel Insights Oncology report: https://lnkd.in/e_YrUJY4 #PrecisionOncology #Regulatory #NovelInsights
-
-
Biotech and pharma companies - How do we determine the most efficient regulatory path for codeveloped companion diagnostic tests (CDx)? A CDx can significantly maximize return on investment in clinical trials, but transitioning from a research-grade to a clinical-grade assay can present resource management challenges, especially for emerging companies. Regulatory experts Mwango Kashoki and Sinan Sarac share how to minimize time and resources in our New Medicines, Novel Insights Oncology report: https://lnkd.in/eCecPDg7 #PrecisionOncology #ParexelBiotech #NovelInsights
-
-
Biotech and pharma companies - How do we determine the most efficient regulatory path for codeveloped companion diagnostic tests (CDx)? A CDx can significantly maximize return on investment in clinical trials, but transitioning from a research-grade to a clinical-grade assay can present resource management challenges, especially for emerging companies. Regulatory experts Mwango Kashoki and Sinan Sarac share how to minimize time and resources in our New Medicines, Novel Insights Oncology report: https://lnkd.in/eNiy26EP #PrecisionOncology #Regulatory #NovelInsights
-
-
Biotech and pharma companies - How do we determine the most efficient regulatory path for codeveloped companion diagnostic tests (CDx)? A CDx can significantly maximize return on investment in clinical trials, but transitioning from a research-grade to a clinical-grade assay can present resource management challenges, especially for emerging companies. Regulatory experts Mwango Kashoki and Sinan Sarac share how to minimize time and resources in our New Medicines, Novel Insights Oncology report: https://lnkd.in/gqJgs_z8 #PrecisionOncology #Regulatory #NovelInsights
-
-
Top Voice for R&D and Venture Investing: Imaging | Technology | Clinical Trials |
😀 Finally we see #treatment success reflected through both #pain and #inflammation reduction in #osteoarthritis patients (quantified with #DCEMRI, IAG, IMAGE ANALYSIS GROUP). ♥ It was such a pleasure and privilege to present the #imaging efficacy data for these two studies, designed and run by Paradigm Biopharmaceuticals and Eupraxia Pharmaceuticals Inc. 💊 This year's Clinical Trial Symposium at #OARSI brought focus on the new technologies for #OA #imaging and #biomarker science. I believe that by #innovating, we will reach the target of disease modifying #osteoarthritis drugs and impactful evidence of univocal #patient response in our #trials. With Morten Asser Karsdal, Ali Mobasheri, Mikael Boesen, Ali Guermazi, MD, PhD, Philip Conaghan, Felix Eckstein, John Carrino, Dr. Alex I., Alan Brett PhD, Loeser Richard, Anne C. Bay-Jensen, Christoph Ladel, Virginia Kraus, Jérémie SELLAM, Mona Dvir-Ginzberg, Mohit Kapoor who contributed their time and knowledge to make #OARSI24 the worldwide success. Look forward to the next meeting in 2025! Presented by James Helliwell & Amanda Malone for Eupraxia and Paul Rennie and Mukesh Ahuja for Paradigm)
-
Biotech and pharma companies - How do we determine the most efficient regulatory path for codeveloped companion diagnostic tests (CDx)? A CDx can significantly maximize return on investment in clinical trials, but transitioning from a research-grade to a clinical-grade assay can present resource management challenges, especially for emerging companies. Regulatory experts Mwango Kashoki and Sinan Sarac share how to minimize time and resources in our New Medicines, Novel Insights Oncology report: https://lnkd.in/eDJ7B7Nx #PrecisionOncology #Regulatory #NovelInsights
-
-
Biotech and pharma companies - How do we determine the most efficient regulatory path for codeveloped companion diagnostic tests (CDx)? A CDx can significantly maximize return on investment in clinical trials, but transitioning from a research-grade to a clinical-grade assay can present resource management challenges, especially for emerging companies. Regulatory experts Mwango Kashoki and Sinan Sarac share how to minimize time and resources in our New Medicines, Novel Insights Oncology report: https://lnkd.in/gw9eFZ_Y #PrecisionOncology #ParexelBiotech #NovelInsights
-
-
Root Cause Analysis Lead | 13+ Years in Quality Management | Driving Continuous Improvement & Operational Excellence | DE&I Ally
Biotech and pharma companies - How do we determine the most efficient regulatory path for codeveloped companion diagnostic tests (CDx)? A CDx can significantly maximize return on investment in clinical trials, but transitioning from a research-grade to a clinical-grade assay can present resource management challenges, especially for emerging companies. Regulatory experts Mwango Kashoki and Sinan Sarac share how to minimize time and resources in our New Medicines, Novel Insights Oncology report: https://lnkd.in/dFN2ifiF #PrecisionOncology #Regulatory #NovelInsights
-
-
Biotech and pharma companies - How do we determine the most efficient regulatory path for codeveloped companion diagnostic tests (CDx)? A CDx can significantly maximize return on investment in clinical trials, but transitioning from a research-grade to a clinical-grade assay can present resource management challenges, especially for emerging companies. Regulatory experts Mwango Kashoki and Sinan Sarac share how to minimize time and resources in our New Medicines, Novel Insights Oncology report: https://lnkd.in/e95Bds_G #PrecisionOncology #Regulatory #NovelInsights
-
